|
gptkbp:instance_of
|
gptkb:vaccine
|
|
gptkbp:administration_age_group
|
12 years and older
|
|
gptkbp:clinical_trial
|
multiple countries
Phase 3
|
|
gptkbp:clinical_trial_end_date
|
January 2021
|
|
gptkbp:clinical_trial_start_date
|
July 2020
|
|
gptkbp:developed_by
|
gptkb:Pfizer
gptkb:Bio_NTech
|
|
gptkbp:dosage_form
|
yes
|
|
gptkbp:dosing_interval
|
3 weeks
|
|
gptkbp:first_dose
|
two doses required
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
BNT162b11
|
|
gptkbp:is_effective_against
|
95% effective
|
|
gptkbp:is_vulnerable_to
|
gptkb:international_collaboration
gptkb:significant
December 2020
global
generally positive
adverse event reporting
rapid development
public and private sectors
equitable access
requires trained personnel
preventive vaccine
reduces transmission
against variants
reduces hospitalization
reduces severe disease
important for uptake
m RNA technology
requires ultra-cold freezers
|
|
gptkbp:manufacturer
|
gptkb:Pfizer-Bio_NTech
|
|
gptkbp:market
|
ongoing
|
|
gptkbp:marketed_as
|
gptkb:Comirnaty
|
|
gptkbp:mechanism_of_action
|
induces immune response
|
|
gptkbp:regulatory_compliance
|
Emergency Use Authorization
|
|
gptkbp:route_of_administration
|
intramuscular
|
|
gptkbp:safety_measures
|
VAERS
|
|
gptkbp:side_effect
|
fatigue
headache
muscle pain
fever
joint pain
chills
|
|
gptkbp:storage
|
-70° C
|
|
gptkbp:supply_chain
|
cold chain logistics
|
|
gptkbp:targets
|
gptkb:COVID-19
|
|
gptkbp:type
|
gptkb:vaccine
|
|
gptkbp:uses_technology
|
lipid nanoparticles
|
|
gptkbp:vaccine_approval_authority
|
gptkb:FDA
gptkb:WHO
gptkb:EMA
|
|
gptkbp:vaccine_communication_strategy
|
public awareness campaigns
|
|
gptkbp:vaccine_crisis_management
|
critical during pandemic
|
|
gptkbp:vaccine_efficacy_duration
|
6 months
|
|
gptkbp:vaccine_ethical_considerations
|
informed consent required
|
|
gptkbp:vaccine_global_distribution
|
collaboration with COVAX
|
|
gptkbp:vaccine_impact_on_herd_immunity
|
contributes to herd immunity
|
|
gptkbp:vaccine_long_term_effects
|
under investigation
|
|
gptkbp:vaccine_public_health_guidelines
|
followed by healthcare providers
|
|
gptkbp:vaccine_regulatory_compliance
|
strict adherence required
|
|
gptkbp:vaccine_research_ongoing
|
yes
|
|
gptkbp:vaccine_research_publications
|
numerous studies published
|
|
gptkbp:wholisting
|
yes
|
|
gptkbp:bfsParent
|
gptkb:Bio_NTech
|
|
gptkbp:bfsLayer
|
5
|